Solventum Corporation (SOLV) Institutional Ownership & Insider Trading

877 institutions reported holding Solventum Corporation shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 1 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

SOLVSolventum CorporationFollow SOLV — free

Medical Instruments & Supplies · Healthcare

—

Price chart with a free account

Market cap: 14.5B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 5 Nov, in 12 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

877 institutions held 75.0% of the shares. Across filers that reported both quarters, shares held changed -2.1%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	877	128	-2.1%	225	82	250	91
Mar 26	870	129	+3.7%	237	43	245	94
Dec 25	917	126	+1.4%	219	71	262	44
Sep 25	840	122	+7.8%	228	45	230	54
Jun 25	866	115	+0.1%	197	40	302	58
Mar 25	886	112	+5.1%	187	51	313	68
Dec 24	910	110	+1.6%	176	44	348	87
Sep 24	906	104	+0.3%	152	116	385	74

Solventum Corporation — questions

Who owns Solventum Corporation stock?: 877 institutions reported Solventum Corporation shares in 13F filings for the quarter ended 2026-06-30. The largest: Independent Franchise Partners LLP (9.5%), BlackRock, Inc. (5.7%), VANGUARD CAPITAL MANAGEMENT LLC (5.7%).
Are Solventum Corporation insiders buying or selling?: 1 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Solventum Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.